Healthium Medtech Limited Files DRHP with SEBI

MUMBAI:
Healthium Medtech Limited a global medtech company focused on products used in surgical, post-surgical and chronic care, has filed its Draft Red Herring Prospectus (“DRHP”) with market regulator Securities and Exchange Board of India (“SEBI”). The company plans to raise funds via Initial Public offerings through fresh issue aggregating up to Rs. 390 crores (The “Fresh Issue”) and an “Offer for Sale (OFS)” comprising up to 39,100,000 equity shares. The OFS comprises upto 39,000,000 equity shares by Quinag Acquisition (FDI) Limited (“Promoter Selling Shareholders”) and up to 100,000 equity shares by Mahadevan Naryanamoni (“Individual Selling Shareholder”).

Healthium Medtech is the largest independent medical device company and is the second-largest company overall, in the surgical consumables market in India with a 7.91% share based on value in fiscal 2021. The Company operates across three key markets, namely, India, UK and rest of the world and four focus areas, namely, advanced surgery, urology, arthroscopy and wound care. Along with the largest independent medical device company it is also the largest non-captive surgical needles manufacturer, with a 22.30% share in overall volume sales globally, and 45.41% share of the non-captive market. It is one of the largest independent medical device companies and the third-largest company overall in the urology collection devices market in the UK, with a 13.96% market share.

The company proposes to utilise net proceed from the issue towards funding (i) Repayment and/or pre-payment, in full or part, of certain borrowings availed by our Company; (ii) Investment into our Subsidiaries, Sironix Medical Technologies B.V. (“Sironix”), Clinisupplies Limited (“Clinisupplies”) and Quality Needles Private Limited (“Quality Needles”); (iii) Acquisitions and other strategic initiatives; and (iv) General corporate purposes

The Book Running Lead Managers to the offer are ICICI Securities Limited, CLSA India Private Limited, Credit Suisse Securities (India) Private Limited and Nomura Financial Advisory and Securities (India) Private Limited. The Legal Counsel to the company and the Promoter Selling Shareholder as to Indian Law is Cyril Amarchand Mangaldas, the Legal Counsel to the BRLMs as to Indian Law is Khaitan & Co and the International Legal Counsels to the BRLMs is White & Case Pte. Ltd.

The equity shares are proposed to be listed on BSE and NSE.